Compare Nuwellis Inc (NUWE) vs Sunrun Inc (RUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Sunrun Inc — how do they compare? Nuwellis Inc trades at $0.68 (market cap $2.20M), while Sunrun Inc trades at $7.67 (market cap $1.83B). The key difference: Sunrun Inc is far larger — about 831.8× Nuwellis Inc's market cap, and Nuwellis Inc is more actively traded (121,544 versus 13,379,830). Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Sunrun Inc for 16 Days on average.
| NUWE | RUN | |
|---|---|---|
Market Cap | $2.20M | $1.83B |
Volume | 121,544 | 13,379,830 |
Sector | Health | Energy |
52-Week High | $146.65 | $21.41 |
52-Week Low | $0.68 | $7.59 |
Typical Hold Time | 26 Days | 16 Days |
Enterprise Value | -$1.52M | $16.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Sunrun (RUN) trades at $7.61, down 2.06% amid broader solar sector weakness. The stock shows bearish technical signals with oversold RSI levels, while fundamentals reveal strong earnings beats but negative operating cash flow. Recent partnerships with Tesla and Voltus highlight growth potential in distributed energy, though high borrowing costs pressure project financing.
Wall Street maintains a bullish consensus with a $16.56 price target (62% buy ratings), but risks include persistent cash burn, interest expense burden, and solar industry headwinds. The stock trades at discounted valuations (P/E 5.18, P/B 0.53) but requires improved profitability to justify analyst optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →
